Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with chemotherapy within its marketing authorisation for untreated advanced gastric or gastro-oesophageal junction cancer.
 
Status In progress
Process STA 2018
ID number 1465

Provisional Schedule

Expected publication 02 September 2020

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-October 2019 when we will write to you about how you can get involved.
22 March 2019 In progress, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid July 2019 when we will write to you about how you can get involved.
17 January 2019 - 14 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 April 2018 Referral
24 April 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance